Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

253.35 +10.21 (+4.20%)
Official Closing Price Updated: 7:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 52,635,083
Open 245.26
Bid (Size) 252.50 (200)
Ask (Size) 253.40 (100)
Prev. Close 243.14
Today's Range 244.66 - 253.35
52wk Range 181.73 - 253.35
Shares Outstanding N/A
Dividend Yield 2.73%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? ↗
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is AbbVie a Buy After Its Purchase of Apogee? ↗
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion? 
Via The Motley Fool

Performance

YTD
+10.5%
+10.5%
1 Month
+15.9%
+15.9%
3 Month
+18.9%
+18.9%
6 Month
+9.8%
+9.8%
1 Year
+39.0%
+39.0%

More News

Read More
News headline image
The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
From Biotech Insider
Via GlobeNewswire
News headline image
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years ↗
Via Benzinga
AbbVie Inc (NYSE:ABBV) Breakout Setup Combines Strong Technical Rating with High-Quality Consolidation Entry ↗
Via Chartmill
News headline image
2 Value Stocks Worth Your Attention and 1 Facing Headwinds
Via StockStory
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Why AbbVie Stock Jumped Today ↗
Via The Motley Fool
News headline image
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? ↗
Via The Motley Fool
Monday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
From Brodsky & Smith LLC
Via GlobeNewswire
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
5 Dividend Stocks to Buy and Hold Forever ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Excellent Dividend Stocks to Buy on the Dip ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Profitable Stocks Worth Your Attention and 1 We Avoid
Via StockStory
News headline image
How Many Botox Units Do You Need: Forehead, Crow's Feet, and Frown Lines
Via Press Release Distribution Service
News headline image
3 High-Yield Dividend Stocks to Buy Hand Over Fist in June ↗
Via The Motley Fool
Topics Economy
News headline image
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend. ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
The Best Stocks to Invest $500 in Right Now ↗
Via The Motley Fool
News headline image
Dry eye syndrome drugs Market Size, Industry Report By 2035 ↗
Via Talk Markets
Topics Economy
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street ↗
Via The Motley Fool
Topics ETFs Intellectual Property Stocks
News headline image
Higher Yield or Broader Dividend Diversification? VYM vs. HDV ↗
Via The Motley Fool
Topics ETFs
News headline image
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic ↗
Via The Motley Fool

Frequently Asked Questions

Is AbbVie publicly traded?
Yes, AbbVie is publicly traded.
What exchange does AbbVie trade on?
AbbVie trades on the New York Stock Exchange
What is the ticker symbol for AbbVie?
The ticker symbol for AbbVie is ABBV on the New York Stock Exchange
What is the current price of AbbVie?
The current price of AbbVie is 253.35
When was AbbVie last traded?
The last trade of AbbVie was at 06/26/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.